HTBX - Heat Biologics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.7400
+0.0240 (+3.35%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.7160
Open0.7300
Bid0.7100 x 1100
Ask0.7500 x 1200
Day's Range0.7265 - 0.7700
52 Week Range0.6700 - 2.5300
Volume97,643
Avg. Volume333,487
Market Cap25.209M
Beta (3Y Monthly)3.08
PE Ratio (TTM)N/A
EPS (TTM)-0.7360
Earnings DateFeb 28, 2019 - Mar 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.75
Trade prices are not sourced from all markets
  • Zacks Small Cap Research4 days ago

    HTBX: INDs To Be Filed Soon

    By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT First Quarter 2019 Results Heat Biologics, Inc. (NASDAQ:HTBX) reported first quarter 2019 results in a May 15 release and concurrently ...

  • ACCESSWIRE13 days ago

    Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure

    Clinicalbenefit observed in 55% of patients receiving HS-110 plus nivolumab aftercheckpoint inhibitor treatment failure HS-110 incombination with nivolumab demonstrates clinical activity in low CD8+ TIL ...

  • Is Heat Biologics, Inc.'s (NASDAQ:HTBX) CEO Overpaid Relative To Its Peers?
    Simply Wall St.24 days ago

    Is Heat Biologics, Inc.'s (NASDAQ:HTBX) CEO Overpaid Relative To Its Peers?

    Jeff Wolf has been the CEO of Heat Biologics, Inc. (NASDAQ:HTBX) since 2008. This analysis aims first to contrast CEO...

  • ACCESSWIRE27 days ago

    Heat Biologics to Present at the 20th Annual B. Riley FBR Institutional Investor Conference

    DURHAM, NC / ACCESSWIRE / May 20, 2019 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today announced that it will be presenting at the 20th Annual B. Riley FBR Institutional Investor Conference on Thursday, May 23rd, at 3:00 PM, PST at The Beverly Hilton in Beverly Hills, California. Jeff Wolf, Chief Executive Officer of Heat Biologics, will be presenting a company overview. Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using CD8+ "Killer" T-cells.

  • ACCESSWIRElast month

    Heat Biologics Reports First Quarter 2019 Results and Provides Corporate Update

    On track to complete enrollment of Phase 2 lung cancer trial in Q2 2019 and report additional interim data in Q4 2019 Anticipates receiving additional $6.9 million in grant funds after filing PTX-35 IND ...

  • ACCESSWIRElast month

    Heat Biologics Lead Director to Present at the ChinaBio 2019 Conference in Shanghai

    DURHAM, NC / ACCESSWIRE / May 6, 2019 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, today ...

  • ACCESSWIRE2 months ago

    Heat Biologics CEO to Present at the ThinkEquity Conference in New York City

    DURHAM, NC / ACCESSWIRE / April 18, 2019 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, announces ...

  • Zacks Small Cap Research2 months ago

    HTBX: 2018 Financial & Operational Results

    By John Vandermosten, CFA NASDAQ:HTBX READ THE LATEST HTBX RESEARCH REPORT Full Year 2018 Results Heat Biologics, Inc. (NASDAQ:HTBX) reported full year 2018 results in a March 28 release and concurrently ...

  • ACCESSWIRE2 months ago

    Heat Biologics Delivers Poster Presentation at the AACR Annual Meeting 2019

    DURHAM, NC / ACCESSWIRE / April 2, 2019 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, announces that it delivered a poster presentation yesterday, April 1, 2019, at the American Association for Cancer Research (AACR) Annual Meeting. The Company's presentation, entitled, ''Generation of a novel, allogeneic cell-based, Gp96-Ig/OX40L cancer vaccine, improves anti-tumor immunity and long-term memory T-cell generation,'' is available online here. The poster presentation featured the Company's next generation cellular vaccine platform, ComPACT (COMbination Pan-Antigen Cytotoxic Therapy), which incorporates a tumor antigen chaperone (gp96-Ig) with T-cell costimulation (OX40L-Ig), simulating a single tumor cell line source that secretes both products.

  • ACCESSWIRE3 months ago

    Heat Biologics Reports 2018 Results and Provides Corporate Update

    Recently announced interim HS-110 Phase 2 data demonstrating survival benefit in patients with ‘cold' tumors (CD8+ TILs

  • ACCESSWIRE3 months ago

    Heat Biologics to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy

    DURHAM, NC / ACCESSWIRE / March 21, 2019 / Heat Biologics,Inc. (HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, today announced an oral presentation to be held at the Chinese Society for Clinical Oncology (CSCO) Conference on Immunotherapy, endorsed by the American Association for Cancer Research (AACR), taking place in Shanghai, China. The oral session will be held on March 22, 2019 from 17:00 China Standard Time.

  • Zacks Small Cap Research3 months ago

    HTBX: HS-110 Interim Update

    By John Vandermosten, CFA NASDAQ:HTBX Heat Biologics, Inc. (NASDAQ:HTBX) has continued to progress in their HS-110 Durga trial, recently providing interim results at the ASCO-SITC Clinical Immuno-Oncology ...

  • ACCESSWIRE3 months ago

    Heat Biologics Lead Director to Chair Oncology Roundtable Discussion at WuXi Healthcare Forum in Shanghai

    DURHAM, NC / ACCESSWIRE / March 5, 2019 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing "off-the-shelf" T-cell therapies designed to activate a patient's immune system against cancer, today announced that John Prendergast, Heat Biologic's Lead Board member, will chair a roundtable discussion at 4:00-5:00 pm China Standard Time (CST), on Wednesday, March 6, 2019 at the WuXi Healthcare Forum at the St. Regis Shanghai Jingan Hotel. Dr. Prendergast will chair a panel on oncology, which will focus on promising new developments in the space.

  • ACCESSWIRE4 months ago

    Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology Symposium

    - Preliminary data suggests the addition of HS-110 to Nivolumab may restore responsiveness to treatment after tumor progression on prior checkpoint inhibitor therapy - Median overall survival not yet reached ...

  • ACCESSWIRE4 months ago

    These Four Healthcare Stocks Are Heating Up On Tuesday

    Premier Health Group (PHGRF) (PHGI), Heat Biologics Inc (HTBX), Zynerba Pharmaceuticals Inc (ZYNE), and Aurora Cannabis Inc (ACB) represent 4 healthcare stocks to keep on your radar this week. Premier Health Group (PHGRF) (PHGI) today announced plans to expand its development team at Cloud Practice Inc. to support the Company's focus on digitizing health care. The Company recently hired four new full-time employees, three Web Software Developers and one User Interface/User Experience (UI/UX) Designer, to support the build-out of its patient-centric platform and mobile app - a beta version of which will be available by end of Q2.

  • What Type Of Shareholder Owns Heat Biologics, Inc.’s (NASDAQ:HTBX)?
    Simply Wall St.4 months ago

    What Type Of Shareholder Owns Heat Biologics, Inc.’s (NASDAQ:HTBX)?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Heat Biologics, Inc. (NASDAQ:HTBX)Read More...

  • ACCESSWIRE5 months ago

    UPDATE: Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial

    DURHAM, NC / ACCESSWIRE / January 14, 2019 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today announced that it has dosed its first patient in its Phase 2 clinical trial investigating HS-110 in combination with Merck's anti-PD1 checkpoint inhibitor, KEYTRUDA® (pembrolizumab), in patients with advanced non-small cell lung cancer (NSCLC). This expansion of the Company's Phase 2 trial into first-line maintenance treatment with Keytruda follows positive interim results reported last year on previously treated patients receiving HS-110 in combination with Bristol-Myers Squibb's anti-PD-1 checkpoint inhibitor, Opdivo® (nivolumab).

  • ACCESSWIRE5 months ago

    Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial

    DURHAM, NC / ACCESSWIRE / January 14, 2019 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today announced that it has dosed its first patient in its Phase 2 clinical trial investigating HS-110 in combination with Merck's anti-PD1 checkpoint inhibitor, KEYTRUDA® (pembrolizumab), in patients with advanced non-small cell lung cancer (NSCLC). This expansion of the Company's Phase 2 trial into first-line maintenance treatment with Keytruda follows positive interim results reported earlier this year on previously treated patients receiving HS-110 in combination with Bristol-Myers Squibb's anti-PD-1 checkpoint inhibitor, Opdivo® (nivolumab).

  • Benzinga5 months ago

    The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks The following biotech stocks struck 52-week highs Jan. 9:  China SXT Pharmaceuticals Inc (NASDAQ: SXTC ...

  • ACCESSWIRE5 months ago

    Heat Biologics Provides Clinical and Business Update

    DURHAM, NC / ACCESSWIRE / January 10, 2018 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today provided a business update regarding the company's progress and plans for 2019. Jeff Wolf, Heat's CEO, commented, "We have postponed reporting our most recent interim data to enable us to present this data at a leading oncology conference.

  • ACCESSWIRE5 months ago

    Heat Biologics Principal Investigator Selected to Deliver Oral Presentation of New HS-110 Interim Phase 2 Data at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium

    DURHAM, NC / ACCESSWIRE / January 8, 2019 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today announced that the Company's principal investigator for its Phase 2 Lung Cancer Trial, Daniel Morgensztern, MD, Associate Professor of Medicine and Director of Thoracic Oncology, Washington University School of Medicine, has been selected to deliver an oral presentation of his abstract summarizing new interim data from the Company's Phase 2 trial of HS-110 in combination with Bristol-Myers Squibb's anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo®), in patients with advanced non-small cell lung cancer (NSCLC) at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. The 2019 ASCO-SITC Clinical Immuno-Oncology Symposium will be held from February 28-March 2, 2019 at the San Francisco Marriott Marquis.

  • ACCESSWIRE5 months ago

    Heat Biologics to Present at Biotech Showcase 2019 in California

    DURHAM, NC / ACCESSWIRE / January 4, 2019 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced that it will be presenting at the Biotech Showcase 2019 conference on Tuesday, January 8, 2019, at 11:30 a.m. PST in the Yosemite C ballroom at the Hilton San Francisco Union Square. Jeff Wolf, CEO of Heat Biologics, will be presenting. Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using of CD8+ "Killer" T-cells.

  • Zacks Small Cap Research6 months ago

    HTBX: Plenty of Catalysts in 2019

    By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Third Quarter 2018 Results Heat Biologics, Inc. (NASDAQ:HTBX) reported third quarter 2018 results in an August 14th release and ...

  • Durham company rakes in another $13.8M through public offering
    American City Business Journals7 months ago

    Durham company rakes in another $13.8M through public offering

    Heat Biologics just banked an additional $13.8 million in its latest public offering. The Durham-based biopharmaceutical company (Nasdaq: HTBX) announced the public offering last week. It estimated the gross proceeds from the offering to come close to $12 million. At close on Monday, that figure realized an additional $1.8 million.

  • ACCESSWIRE7 months ago

    Heat Biologics, Inc. Announces Closing of $13,800,000 Public Offering

    DURHAM, NC / ACCESSWIRE / November 26, 2018 / Heat Biologics, Inc. (''Heat'') (HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced the closing of its previously announced underwritten public offering of 8,000,000 shares of its common stock together with warrants to purchase 4,000,000 shares of its common stock at a combined price to the public of $1.50. In addition, the underwriter exercised the over-allotment option to purchase an additional 1,200,000 shares of common stock and warrants to purchase 600,000 shares of common stock. Gross proceeds to Heat from this offering are approximately $13,800,000 before deducting underwriting discounts and commissions and other estimated offering expenses payable by Heat.